Recently, it was observed that phenotypic changes in tumor-associated macrophages (TAMs) were responsible for the immunosuppressive mechanism of BRCA-mutated breast cancer, and STING agonists could reverse these changes and enhance anti-tumor effects (Wang et al., 2022). This evidence concerns the gene STING1 and breast carcinoma.